Marc Engelhardt
Fortune : 1 M $ au 31/05/2026
Fortune : 1 M $ au 31/05/2026
Marc Engelhardt is currently Chief Medical Officer at Basilea Pharmaceutica AG since 2018, with employment at the company starting in 2010.
Formerly, Dr. Engelhardt was Director-Global Program Medical at Novartis Pharma AG.
Education includes undergraduate and doctorate degrees from Johann Wolfgang Goethe-Universität Frankfurt am Main.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2025 | 16 061 ( 0,12% ) | 1 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| BASILEA PHARMACEUTICA AG | Directeur Technique/Scientifique/R&D | 01/01/2018 |
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 3 |
|---|---|
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Johann Wolfgang Goethe-Universität Frankfurt am Main
Johann Wolfgang Goethe-Universität Frankfurt am Main Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national